Abstract:Objective: To investigate the long-term prognostic factors of CBFB-MYH11-positive acute myeloid leukemia in low、 intermediate risk patients. Methods:58 CBFB-MYH11-positive patients were analyzed retrospectively in 1525 acute myeloid leukemia patients who were diagnosed in Peking University Institute of Hematology from October 2013 to August 2018, and the clinical feature、induction remission rate and survival were compared. Results: 58 (8%) patients with CBFB-MYH11-positive were found in 1525 newly diagnosed actue myeloid leukemia, 41 males and 17 females were included. The median age was 38(17-66) years , and median follow-up time was 29.8(4.8-74.4)months, 25(43.1%) patients received allogenic hematopoietic stem cell transplantation, in which there were 10 patients with c-kit mutation. According to the NCCN guideline, there were 40 patients in low risk group and 18 patients in intermediate risk group (16 patients with c-kit mutation). The rate of complete remission (CR) in the first induction chemotherapy was 98.3%(57/58), the cumulative remission rate of two cycles was 100%, the relapse rate was 25.9%(15/58), and the mortality rate was 19.0% (11 ≤ 58). After 1 and 2 cycles of consolidation, the level of CBFB-MYH11/ABL decreased to less than 0.18% and 0.094% respectively, which were related to the low recurrence rate. Among the 33 patients who did not undergo allogenic hematopoietic stem cell transplantation after two courses of consolidation, the recurrence rate of patients with CBFB-MYH11/ABL level > 0.1% (n =21) was significantly higher than that of patients with < 0.1% (n = 12) (61.9% VS 0%, P =0. 001), and the relapse-free survival(RFS) (3-year RFS rate 37.6% VS 100%, P =0.005 ) 、event-free survival (EFS)(3-year EFS rate 33. 3% VS 100%, P = 0.004) were significantly decreased. The RFS and EFS were lower than those of patients received allogenic hematopoietic stem cell transplantation (n=25) (3-year RFS rate 31.4% VS 84.6%, P = 0.000; 3-year EFS rate 31.4% VS 76.0%, P =0.004). Conclusions: To the CBFB-MYH11-positive acute myeloid leukemia patients, if the level of CBFB-MYH11/ABL gene presented more than 0.1% at any time after 2 cycles of consolidation, poor prognosis was related to, and allogenic hematopoietic stem cell transplantation could improve the survival. Disclosures No relevant conflicts of interest to declare.

Clinical Significance of Immature Reticulocyte Fraction in Patients with Acute Myeloid Leukemia Following Consolidation Chemotherapy with High-Dose Cytarabine

Factors Affecting Early Death and Survival of Patients with Acute Promyelocytic Leukemia Treated with ATRA-Based Therapy Regimens

Rhg CSF Accelerates Neutrophil Recovery in Acute Leukemia Patients Undergoing Chemotherapy

The Number Of Cd34+Cd38+Cd117+Hla-Dr+Cd13+Cd33+Cells Indicates Post-Chemotherapy Hematopoietic Recovery In Patients With Acute Myeloid Leukemia

Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients

Automated reticulocyte response is a good predictor of bone-marrow recovery in pediatric malignancies

Kinetics of Immune Reconstitution after Anti-Cd19 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute Lymphoblastic Leukemia Patients.

Rapid Early Recovery of Absolute Lymphocyte Counts at Day 30 Can Predict Reduced Risk of Relapse in Acute Lymphoblastic Leukemia Following Haploidentcial Allogeneic Stem Cell Transplantation

Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia.

The Prognostic Value Of The Peripheral Blood Cell Counts Changes During Induction Chemotherapy In Chinese Patients With Adult Acute Myeloid Leukemia

The Lost or Absence of MRD < 0.1% at Any Time after 2 Cycles of Consolidation Chemotherapy in CBFB-MYH11-Positive Acute Myeloid Leukemia Indicates Poor Prognosis

Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies.

Prognostic value of postinduction medullary myeloid recovery by flow cytometry in acute myeloid leukemia

Correlation Between ALIP-like Cluster and Fibrous Proliferation in Bone Marrow of Patients with Acute Myeloid Leukemia in CR Phase

Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission

Clinical significance of peripheral reticulocyte percentage in monitoring bone marrow suppression after solid tumor chemotherapy

Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia

Significance of Monitoring Reticulocyte Count During Chemotherapy for Patients with Cancer

The Clinical Significane of Detecting Minimal Residual Disease with Acute Myeloid Leukemia by Flow Cytometry

[Prognostic significance of blood count at the time of achieving morphologic leukemia-free state in adults with acute myeloid leukemia].

[The Comparison of Predicting Clinical Outcomes Between Immunolophenotype and Hematological Complete Remission Before Human Leukocyte Antigen-Matched Sibling Donor Transplantation in Acute Myeloid Leukemia].